Evidence mapPaperPMID 37020802Full record

ArticleDrug design, development and therapy2023

5-Fluorouracil Combined with Rutaecarpine Synergistically Suppresses the Growth of Colon Cancer Cells by Inhibiting STAT3.

Zhen Yu, Shixin Chan, Xu Wang, Rui Sun, Ming Wang, Zhenglin Wang, Xiaomin Zuo, Jiajie Chen, Huabing Zhang, Wei Chen

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhen Yu *Department of General Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.ORCID 0000-0002-1836-4350
Shixin Chan *Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Xu WangDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Rui SunDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Ming WangDepartment of General Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.ORCID 0000-0003-3215-9967
Zhenglin WangDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Xiaomin ZuoDepartment of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.ORCID 0000-0002-8295-7556
Jiajie ChenDepartment of Dermatology, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Huabing ZhangDepartment of Biochemistry & Molecular Biology, School of Basic Medicine, Anhui Medical University, Hefei, 230032, People's Republic of China.
Wei ChenDepartment of General Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, People's Republic of China.
Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the effect of 5-fluorouracil (5-FU) combined with rutaecarpine (RUT) on the antiproliferative, anti-migratory, and apoptosis-promoting ability of colorectal cancer (CRC) cells and explore the underlying mechanism. Methods: The antiproliferative effects of RUT and 5-FU on CRC cells were evaluated using MTT and colony formation assays. Anti-migration was assessed by cell scratch and transwell tests. The synergistic effect of RUT and 5-FU was assessed by isobologram and combination index analysis using CompuSyn software. The effects of RUT and 5-FU on cell apoptosis were detected by flow cytometry. Differences in protein expression levels with or without RUT and/or 5-FU treatment were assessed by Western blot. Moreover, a mouse xenograft model of CRC was established to investigate the antitumor effect of RUT and 5-FU in vivo, and Ki67 and cleaved caspase-3 expression was detected by immunofluorescence. Results: In this study, we found that 5-FU combined with RUT can inhibit the proliferative, migratory, and antiapoptotic abilities of CRC cells to a significantly greater extent than either RUT or 5-FU alone both in vivo and in vitro. Western blot analysis showed that the level of signal transducer and activator of transcription 3 (STAT3) phosphorylation in CRC cells was significantly reduced after combination therapy compared with that seen with the respective monotherapies. In addition, combination therapy influenced the STAT3 signaling pathway, namely, it inhibited the expression of c-Myc, CDK4, and Bcl-2 while enhancing that of the proapoptotic protein cleaved caspase-3. Immunofluorescence staining further showed that the expression of Ki67 and cleaved caspase-3 was significantly downregulated and upregulated, respectively, in tumor tissues of mice treated with combination therapy compared with that observed with 5-FU treatment alone. Conclusion: Combined therapy with 5-FU and RUT exerted a superior curative effect in CRC than treatment with either single drug alone and has potential as a novel therapeutic modality for the treatment of CRC.

Indexed as

Colonic NeoplasmsFluorouracilAnimalsCaspase 3Cell Line, TumorHumansIndole AlkaloidsKi-67 AntigenMiceQuinazolinonesSTAT3 Transcription FactorCaspase 3FluorouracilIndole AlkaloidsKi-67 AntigenQuinazolinonesrutecarpineSTAT3 protein, humanSTAT3 Transcription Factor5-fluorouracilcolorectal cancerrutaecarpinesignal transducer and activator of transcription 3synergistic therapy

Identifiers

PMID37020802
PMCPMC10069641
OpenAlexW4361280333

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.